轻度哮喘的管理:含ICS缓解药物的疗效综述
本综述评估轻度哮喘患者使用含吸入性糖皮质激素(ICS)的缓解药物与短效β2受体激动剂(SABA)或与维持ICS加SABA缓解方案的疗效比较。共纳入9项研究,其中4项最新研究比较ICS/福莫特罗与SABA作为缓解药物。含ICS的缓解药物优于单用SABA缓解,且与维持ICS加SABA缓解等效,尤其在降低重度哮喘急性发作风险方面。
要点
- SABA不应在没有ICS的情况下作为缓解药物使用。
- 轻度哮喘患者对每日维持ICS依从性差,应考虑ICS/福莫特罗替代维持ICS。
- 含ICS的缓解药物在降低重度急性发作风险方面优于单用SABA。
核心结论
- 含ICS的缓解药物优于单用SABA缓解,且与维持ICS加SABA缓解等效,尤其在降低重度哮喘急性发作风险方面。
- SABA不应在没有ICS的情况下作为缓解药物使用。
- 对于轻度哮喘患者,应考虑ICS/福莫特罗作为治疗选择而非维持ICS,以避免患者仅使用SABA的风险。
研究设计与样本
- 本综述评估了9项在轻度哮喘患者中评价含ICS缓解药物的研究。
- 其中4项最新研究比较了ICS/福莫特罗与SABA作为缓解药物。
主要发现
- 含ICS的缓解药物优于单用SABA缓解。
- 含ICS的缓解药物与维持ICS加SABA缓解等效,尤其在降低重度哮喘急性发作风险方面。
临床怎么用
- SABA不应在没有ICS的情况下作为缓解药物使用。
- 对于轻度哮喘患者,应考虑ICS/福莫特罗作为治疗选择而非维持ICS,以避免患者仅使用SABA的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inhaled corticosteroids (ICSs) have been recommended as a maintenance treatment, either alone or together with long-acting inhaled β2-agonists, for all asthma patients. Short-acting β2-agonists (SABAs) are rapid-onset bronchodilators, which provide symptom relief, but have no anti-inflammatory properties, yet are the most widely used as-needed reliever treatment for asthma and often the only treatment prescribed. Asthma patients can find adhering to daily preventative medication with ICS difficult and will often revert to using as-needed SABA as their only treatment, increasing their risk of exacerbations. The purpose of this review is to evaluate the efficacy of reliever medications that contain ICS compared with SABA as reliever, or with maintenance ICS and SABA as reliever, in mild asthma patients.Nine studies were identified that have evaluated the use of ICS as a component of an as-needed reliever in patients with mild asthma. Four of the most recent studies compared the combination of ICS/formoterol to SABA as reliever.ICS-containing reliever medication was superior to SABA as reliever alone, and was equivalent to maintenance ICS and SABA as reliever, particularly in reducing risks of severe asthma exacerbations, in studies which compared these reliever options.SABAs should not be used as a reliever without ICS. The concern about patients with mild asthma not being adherent to maintenance ICS supports a recommendation that ICS/formoterol should be considered as a treatment option instead of maintenance ICS, to avoid the risk of patients reverting to SABA alone.
引用
- O'Byrne PM, Reddel HK, Beasley R, et al. The management of mild asthma. Eur Respir J. 2021. PMID: 33093120. doi:10.1183/13993003.03051-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。